STLNStarling Oncology, Inc.
Services-Offices & Clinics Of Doctors Of Medicine
- Revenue
- $503M
- 28% YoY
- Operating margin
- -7.2%
- 53% YoY
- EBITDA
- −$29M
- 46% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $80M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-0% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $203M | $252M | $324M | $393M | $503M | 28% |
| Operating income | −$46M | −$82M | −$77M | −$60M | −$36M | 40% |
| Net income | −$11M | $152K | −$83M | $64.7B | $60.6B | 6.3% |
| Operating cash flow | −$33M | −$62M | −$36M | −$27M | −$25M | 7.4% |
| Capex | $3M | $6M | $5M | $4M | $3M | 16% |
| Stock-based comp | $25M | $28M | $18M | $11M | $5M | 59% |
| Buybacks | $0 | $9M | $1M | $0 | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $8M | 175 | — |
| FY2024 | $1M | −$511K | 15 | — |